Akinyemi Oni-Orisan, PharmD, PhD

Assistant Professor
Clinical Pharmacy
[email protected]
+1 415 502-7551

The long-term research goal of Dr. Oni-Orisan’s lab is to improve pharmacological regimens for the prevention and treatment of cardiovascular disease in diverse populations through precision medicine. To accomplish this objective, his group combines computational approaches in pharmacogenomics and pharmacoepidemiology using electronic health record-linked biobanks. His lab is currently funded to investigate genetic determinants of efficacy and safety for statin therapy in diverse populations.

Dr. Oni-Orisan teaches and mentors pharmacy students in the Discovery Projects research program including leading the inaugural Health Disparities Discovery Group.

Dr. Oni-Orisan serves as Diversity Leader for the Department of Clinical Pharmacy to champion diversity, equity and inclusion (DEI) efforts in the department.

Publications: 

Perceptions of Older Men Using a Mobile Health App to Monitor Lower Urinary Tract Symptoms and Tamsulosin Side Effects: Mixed Methods Study.

JMIR Human Factors

Wang EY, Breyer BN, Lee AW, Rios N, Oni-Orisan A, Steinman MA, Sim I, Kenfield SA, Bauer SR

Tracking Lower Urinary Tract Symptoms and Tamsulosin Side Effects Among Older Men Using a Mobile App (PERSONAL): Feasibility and Usability Study.

JMIR formative research

Lee AW, Kenfield SA, Wang EY, Enriquez A, Oni-Orisan A, Steinman MA, Sim I, Breyer BN, Bauer SR

QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System.

Journal of the American Heart Association

Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Jorgenson E, Iribarren C

Torsade de pointes: A nested case-control study in an integrated healthcare delivery system.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Iribarren C

MP28-03 PERCEPTIONS OF OLDER MEN USING A MOBILE HEALTH APPLICATION TO MONITOR LOWER URINARY TRACT SYMPTOMS AND TAMSULOSIN ADVERSE EFFECTS: MIXED-METHODS STUDY.

Investigative Urology

Elizabeth Y. Wang, Benjamin N. Breyer, Austin Lee, Natalie Rios, Akinyemi Oni-Orisan, Michael A. Steinman, Ida Sim, Stacey A. Kenfield, Scott R. Bauer

Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network.

Clinical pharmacology and therapeutics

Giacomini KM, Karnes JH, Crews KR, Monte AA, Murphy WA, Oni-Orisan A, Ramsey LB, Yang JJ, Whirl-Carrillo M

Effect of SLCO1B1 T521C on Statin-related Myotoxicity with Use of Lovastatin and Atorvastatin.

Clinical pharmacology and therapeutics

Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Iribarren C, Krauss RM, Risch N, Oni-Orisan A

Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing.

Clinical and translational science

Oni-Orisan A, Srinivas N, Mehta K, Lohy Das J, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA

Embracing Genetic Diversity to Improve Black Health.

The New England journal of medicine

PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms.

Frontiers in Digital Health

Bauer SR, Breyer BN, Oni-Orisan A, Steinman MA, Sim I, McCulloch CE, Kenfield SA

The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change.

npj Genomic Medicine

Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ

Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.

Pharmacogenetics and genomics

Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Risch N, Oni-Orisan A, Jelalian AT, Rettie AE, Liu VX, Schaefer CA

Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.

Circulation. Genomic and precision medicine

Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N

Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.

Prostaglandins & other lipid mediators

Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR

Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.

Pharmacogenomics

Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T

Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding.

The Journal of clinical investigation

Bai X, Mangum KD, Dee RA, Stouffer GA, Lee CR, Oni-Orisan A, Patterson C, Schisler JC, Viera AJ, Taylor JM, Mack CP

Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study.

Journal of lipid research

Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR

Epoxyeicosatrienoic acids and cardioprotection: the road to translation.

Journal of molecular and cellular cardiology

Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM

Acute decompensated heart failure: evolving literature and implications for future practice.

Pharmacotherapy

Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH, Rodgers JE

Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice.

Prostaglandins & other lipid mediators

Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, Lee CR

Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism.

American journal of physiology. Endocrinology and metabolism

Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR